Please enter exact key words
Out-Licensing

We Can Do Better Together

Home / Out-Licensing

Out-Licensing

Protheragen is specialized in discovering and developing innovative therapeutics for the treatment of various cancers and other indications with significant unmet need. Currently, we have several promising pipelines in preclinical phase, including monoclonal antibody and CAR-T products.

We are interested in exploring strategic collaborations with partners, including:

1) licensing the programs from our pipeline or technology from our platform;

2) collaborating with us for the further development of the products in our pipeline to promote the progress to clinic and market, and the costs and future revenue are promised to be shared.

If you are interested, please feel free to contact us so we can discuss more on this technology or product as well as other possible partnering opportunities. Look forward to cooperating with you in the near future.

Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.